CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | DEFR14A: Definitive proxy statement in connection with contested solicitations
CNS Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
CNS Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(3.20%),Steven Boyd(3.20%)
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | DEF 14A: Definitive information statements
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 424B5: Prospectus
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-10% Owner Cortice Biosciences, Inc.
CNS Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-10% Owner Cortice Biosciences, Inc.
CNS Pharmaceuticals | EFFECT: Others
CNS Pharmaceuticals | SC 13D: Statement of acquisition of beneficial ownership by individuals-Cortice Biosciences, Inc.(5.7%)
CNS Pharmaceuticals | RW: Registration Withdrawal Request